Equities Analysts Offer Predictions for ACRV FY2024 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Research analysts at HC Wainwright dropped their FY2024 EPS estimates for shares of Acrivon Therapeutics in a research report issued on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($2.45) for the year, down from their prior forecast of ($2.31). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.45) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q4 2024 earnings at ($0.61) EPS, FY2025 earnings at ($3.43) EPS, FY2026 earnings at ($3.40) EPS, FY2027 earnings at ($2.23) EPS and FY2028 earnings at ($1.49) EPS.

Other equities analysts also recently issued reports about the stock. JMP Securities restated a “market outperform” rating and set a $17.00 target price on shares of Acrivon Therapeutics in a report on Monday, September 16th. BMO Capital Markets dropped their price objective on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating for the company in a research note on Thursday. Piper Sandler Companies reaffirmed a “buy” rating and set a $30.00 price target on shares of Acrivon Therapeutics in a research report on Friday, September 6th. Finally, LADENBURG THALM/SH SH raised shares of Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Monday, September 16th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $23.67.

Acrivon Therapeutics Trading Down 12.1 %

Shares of Acrivon Therapeutics stock opened at $6.96 on Monday. The stock has a market cap of $216.73 million, a PE ratio of -2.58 and a beta of 0.66. The company has a 50-day moving average of $7.78 and a two-hundred day moving average of $7.77. Acrivon Therapeutics has a 12-month low of $3.19 and a 12-month high of $11.90.

Hedge Funds Weigh In On Acrivon Therapeutics

Hedge funds have recently bought and sold shares of the company. American International Group Inc. grew its stake in Acrivon Therapeutics by 39.2% during the 1st quarter. American International Group Inc. now owns 6,016 shares of the company’s stock worth $43,000 after buying an additional 1,695 shares during the last quarter. Rhumbline Advisers boosted its stake in Acrivon Therapeutics by 48.9% during the second quarter. Rhumbline Advisers now owns 16,209 shares of the company’s stock valued at $94,000 after buying an additional 5,320 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in Acrivon Therapeutics during the second quarter worth about $58,000. XTX Topco Ltd bought a new stake in Acrivon Therapeutics in the second quarter worth about $61,000. Finally, Barclays PLC lifted its holdings in Acrivon Therapeutics by 51.2% in the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after acquiring an additional 11,273 shares during the last quarter. 71.62% of the stock is currently owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.